In the article on sex-specific survival advantage with parathyroid hormone— related protein in the January 15, 2006 issue of Clinical Cancer Research, the column heads in Table 2 were reversed. The correct table appears here.
Table 2.
Demographic and lung cancer data by sex and tumor PTHrP expression
| . | All patients . | . | Females . | . | Males . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | PTHrP-negative . | PTHrP-positive . | PTHrP-negative . | PTHrP-positive . | PTHrP-negative . | PTHrP-positive . | ||||||
| Total no. | 134 (100) | 273 (100) | 46 (100) | 78 (100) | 88 (100) | 194 (100) | ||||||
| Stage | ||||||||||||
| I | 73 (53) | 153 (56) | 27 (59) | 48 (61) | 46 (52) | 104 (54) | ||||||
| II | 14 (10) | 29 (11) | 2 (4) | 3 (4) | 12 (14) | 26 (13) | ||||||
| III | 30 (22) | 39 (14) | 8 (17) | 9 (12) | 22 (25) | 30 (16) | ||||||
| IV | 10 (7) | 13 (5) | 8 (17) | 5 (6) | 2 (2) | 8 (4) | ||||||
| Unknown | 11 (8) | 39 (14) | 5 (11) | 13 (17) | 6 (7) | 26 (13) | ||||||
| Histology | ||||||||||||
| Adenocarcinoma | 56 (42) | 136 (50) | 17 (37)* | 46 (59)* | 39 (44) | 89 (46) | ||||||
| Squamous | 65 (47) | 114 (41) | 24 (52)* | 27 (35)* | 41 (47) | 87 (45) | ||||||
| Large cell | 12 (8) | 22 (8) | 5 (11)* | 5 (6)* | 7 (8) | 17 (8) | ||||||
| Unknown | 1 (1) | 1 (1) | 0 (0)* | 0 (0)* | 1 (1) | 1 (1) | ||||||
| Smoking | ||||||||||||
| Yes | 88 (66) | 193 (71) | 25 (91) | 52 (67) | 63 (72) | 141 (72) | ||||||
| No | 4 (4) | 18 (7) | 3 (4) | 11 (14) | 3 (3) | 7 (4) | ||||||
| Unknown | 18 (30) | 61 (22) | 18 (5) | 15 (19) | 22 (25) | 46 (24) | ||||||
| Smoker pack-years | 50 (6, 160) | 60 (2, 200) | 50 (6, 100) | 48 (2, 175) | 52 (15, 160) | 60 (3, 200) | ||||||
| Hospital | ||||||||||||
| VASDHS | 28 (21) | 76 (28) | 0 (0)† | 0 (0)† | 28 (32) | 76 (39) | ||||||
| UCSD | 72 (54) | 149 (55) | 30 (65)† | 67 (86)† | 42 (48) | 82 (42) | ||||||
| Cytomyx | 34 (25) | 48 (17) | 16 (35)† | 11 (14)† | 18 (20) | 36 (19) | ||||||
| Age (y)‡ | 69 (43, 82)‡ | 64 (19, 89)‡ | 69 (49, 80)‡ | 65 (19, 89)‡ | 69 (43, 82)‡ | 64 (25, 87)‡ | ||||||
| . | All patients . | . | Females . | . | Males . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | PTHrP-negative . | PTHrP-positive . | PTHrP-negative . | PTHrP-positive . | PTHrP-negative . | PTHrP-positive . | ||||||
| Total no. | 134 (100) | 273 (100) | 46 (100) | 78 (100) | 88 (100) | 194 (100) | ||||||
| Stage | ||||||||||||
| I | 73 (53) | 153 (56) | 27 (59) | 48 (61) | 46 (52) | 104 (54) | ||||||
| II | 14 (10) | 29 (11) | 2 (4) | 3 (4) | 12 (14) | 26 (13) | ||||||
| III | 30 (22) | 39 (14) | 8 (17) | 9 (12) | 22 (25) | 30 (16) | ||||||
| IV | 10 (7) | 13 (5) | 8 (17) | 5 (6) | 2 (2) | 8 (4) | ||||||
| Unknown | 11 (8) | 39 (14) | 5 (11) | 13 (17) | 6 (7) | 26 (13) | ||||||
| Histology | ||||||||||||
| Adenocarcinoma | 56 (42) | 136 (50) | 17 (37)* | 46 (59)* | 39 (44) | 89 (46) | ||||||
| Squamous | 65 (47) | 114 (41) | 24 (52)* | 27 (35)* | 41 (47) | 87 (45) | ||||||
| Large cell | 12 (8) | 22 (8) | 5 (11)* | 5 (6)* | 7 (8) | 17 (8) | ||||||
| Unknown | 1 (1) | 1 (1) | 0 (0)* | 0 (0)* | 1 (1) | 1 (1) | ||||||
| Smoking | ||||||||||||
| Yes | 88 (66) | 193 (71) | 25 (91) | 52 (67) | 63 (72) | 141 (72) | ||||||
| No | 4 (4) | 18 (7) | 3 (4) | 11 (14) | 3 (3) | 7 (4) | ||||||
| Unknown | 18 (30) | 61 (22) | 18 (5) | 15 (19) | 22 (25) | 46 (24) | ||||||
| Smoker pack-years | 50 (6, 160) | 60 (2, 200) | 50 (6, 100) | 48 (2, 175) | 52 (15, 160) | 60 (3, 200) | ||||||
| Hospital | ||||||||||||
| VASDHS | 28 (21) | 76 (28) | 0 (0)† | 0 (0)† | 28 (32) | 76 (39) | ||||||
| UCSD | 72 (54) | 149 (55) | 30 (65)† | 67 (86)† | 42 (48) | 82 (42) | ||||||
| Cytomyx | 34 (25) | 48 (17) | 16 (35)† | 11 (14)† | 18 (20) | 36 (19) | ||||||
| Age (y)‡ | 69 (43, 82)‡ | 64 (19, 89)‡ | 69 (49, 80)‡ | 65 (19, 89)‡ | 69 (43, 82)‡ | 64 (25, 87)‡ | ||||||
NOTE: Data are number (% column total)or median (range).
*
P = 0.054, Fisher's exact test, excluding the unknown category.
†
P < 0.05, Fisher's exact test, excluding the VASDHS group.
‡
P < 0.05, PTHrP-positive versus PTHrP-negative patients.
Hastings RH, Laux AMP, Casillas A, et al. Sex-specific survival advantage with parathyroid hormone—related protein in non—small cell lung carcinoma patients. Clin Cancer Res 2006;12:499–506.
American Association for Cancer Research
2006
RSS Feeds